Emerging and potential use of CRISPR in human liver disease

CRISPR technology is rapidly emerging as a transformative tool in the study and treatment of human liver diseases. Its versatility and precision have opened up new possibilities for understanding liver disease mechanisms, developing models, and advancing therapeutic interventions. Below is an in-depth overview of the emerging and potential uses of CRISPR in human liver disease:

### 1. **Gene Therapy for Genetic Liver Diseases**

CRISPR holds immense promise for curing genetic liver disorders by correcting mutations responsible for these conditions. Some notable applications include:

• **Alpha-1 Antitrypsin Deficiency (AATD):** CRISPR can target and repair mutations in the SERPINA1 gene, which cause AATD, a condition leading to liver damage and emphysema.
• **Wilson Disease:** Mutation correction in the ATP7B gene, which is responsible for copper accumulation in the liver, offers potential for treatment.
• **Ornithine Transcarbamylase (OTC) Deficiency:** CRISPR can repair mutations in the OTC gene, which causes urea cycle defects leading to ammonia buildup.
• **Hemochromatosis:** Editing the HFE gene to prevent iron overload in the liver could mitigate the effects of this disease.

### 2. **Treatment of Systemic Disorders via Liver-Directed Editing**

The liver plays a central role in systemic metabolic processes, making it an ideal target for treating systemic disorders. CRISPR is being explored for:

• **Transthyretin Amyloidosis (ATTR):** Liver-directed CRISPR editing of the TTR gene has shown promise in reducing toxic amyloid protein production. Clinical trials, such as NTLA-2001, have demonstrated high efficacy and safety with durable gene silencing.
• **Hypercholesterolemia:** CRISPR-mediated inhibition of the PCSK9 gene in liver cells can significantly lower cholesterol levels. VERVE-101, a base-editing therapy targeting PCSK9, is under clinical investigation.
• **Hemophilia:** Editing the F9 gene to restore factor IX production in hemophilia B patients could offer a long-term cure.

### 3. **Liver Cancer Modeling and Therapy**

CRISPR has revolutionized liver cancer research by enabling rapid development of models and therapeutic approaches:

• **Hepatocellular Carcinoma (HCC) Models:** CRISPR has been used to create mouse models of liver cancer by targeting tumor suppressor genes (e.g., Pten and Trp53). These models help uncover oncogene cooperation and mutation profiles.
• **Gene Screening for Tumorigenesis:** Pooled CRISPR screens have identified essential and suppressive genes involved in liver cancer, aiding in the discovery of therapeutic targets.
• **Potential Therapies:** CRISPR-based approaches could be used to target oncogenes or restore tumor-suppressor gene function in liver cancer patients.

### 4. **Research on Metabolic Liver Diseases**

CRISPR is being employed to study and potentially treat metabolic-associated steatotic liver disease (MASLD), formerly known as NAFLD (non-alcoholic fatty liver disease):

• **Gene Targeting for Lipid Accumulation:** Genes like MRG15 have been identified as drivers of lipid accumulation in the liver, and CRISPR-based approaches could provide therapeutic interventions.
• **Hepatocyte-Specific Studies:** Conditional CRISPR knockouts (e.g., Sh3rf2) are being used to understand liver-cell–specific gene functions related to metabolism and steatosis.

### 5. **Antiviral Applications**

CRISPR screens have identified host genes essential for viral replication, offering potential antiviral targets for hepatitis B virus (HBV) and hepatitis C virus (HCV):

• **HBV:** Genome-wide CRISPR screens revealed genes like ZCCHC14, TRIM26, and FLAD1 as critical for HBV replication. Targeting these genes could pave the way for new antiviral therapies.
• **HCV:** CRISPR could potentially disrupt pathways essential for HCV replication, providing a novel therapeutic strategy.

### 6. **Liver Fibrosis Research and Therapy**

CRISPR screens have uncovered key regulators of liver fibrosis, a major complication of chronic liver diseases:

• **Proteasome Subunits and TGF-β Signaling:** Proteasome subunits were identified as regulators of hepatic stellate cell activation through the TGF-β pathway. Targeting these pathways could prevent or reverse fibrosis progression.
• **Gene Targets:** CRISPR-based approaches could be used to modulate genes involved in fibrosis to promote liver regeneration and healing.

### 7. **Liver Regeneration Studies**

CRISPR is being used to study genes involved in liver regeneration and hepatocyte fitness:

• **FAH−/− Repopulation Model:** This high-throughput in vivo CRISPR screening system is employed to identify genes regulating liver regeneration and hepatocyte survival.
• **Single-Cell CRISPR Integration:** Combining CRISPR editing with single-cell RNA sequencing (scRNA-seq) allows researchers to study gene-specific effects on liver cell heterogeneity and regeneration.

### 8. **Clinical Trials and Therapeutic Progress**

CRISPR-based therapies for liver diseases have entered human clinical trials, demonstrating promising results:

• **NTLA-2001:** A CRISPR-based therapy for TTR amyloidosis has shown durable gene silencing with high efficacy and safety in patients.
• **VERVE-101:** A PCSK9-targeting base-editing therapy for hypercholesterolemia is undergoing clinical evaluation.
• **Future Therapies:** CRISPR holds potential for the development of therapies targeting other liver diseases, such as MASLD and liver cancer.

### 9. **Future Outlook**

CRISPR technology offers unprecedented precision in the study and treatment of liver diseases, but several challenges remain:

• **Delivery Efficiency:** Efficient delivery systems, such as adeno-associated virus (AAV) vectors and lipid nanoparticles, need further optimization for liver-specific targeting.
• **Off-Target Effects:** Ensuring the safety of CRISPR therapies by minimizing unintended edits is a critical area of ongoing research.
• **Ethical Considerations:** The use of CRISPR in humans raises ethical concerns, particularly for germline editing and long-term consequences.

### Conclusion

CRISPR is revolutionizing the field of liver disease research and therapy, enabling precise gene editing to correct genetic disorders, study disease mechanisms, and develop novel treatments. As the technology continues to advance, it holds the potential to provide cures for genetic liver diseases, systemic disorders, liver cancer, fibrosis, and viral infections. However, addressing delivery challenges, off-target effects, and ethical considerations will be essential to fully harness its therapeutic potential.